INmune Bio, Inc.
INMB
$7.32
$0.010.14%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 14.00K | 42.00K | 85.00K | 131.00K | 155.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 14.00K | 42.00K | 85.00K | 131.00K | 155.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 14.00K | 42.00K | 85.00K | 131.00K | 155.00K |
| SG&A Expenses | 9.48M | 9.77M | 10.14M | 9.63M | 9.62M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 42.65M | 41.59M | 37.87M | 34.47M | 29.90M |
| Operating Income | -42.64M | -41.55M | -37.79M | -34.34M | -29.74M |
| Income Before Tax | -42.08M | -41.27M | -37.74M | -34.50M | -30.01M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -42.08 | -41.27 | -37.74 | -34.50 | -30.01 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -42.08M | -41.27M | -37.74M | -34.50M | -30.01M |
| EBIT | -42.64M | -41.55M | -37.79M | -34.34M | -29.74M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -2.13 | -2.18 | -2.06 | -1.92 | -1.67 |
| Normalized Basic EPS | -1.33 | -1.36 | -1.29 | -1.20 | -1.04 |
| EPS Diluted | -2.13 | -2.18 | -2.06 | -1.92 | -1.67 |
| Normalized Diluted EPS | -1.33 | -1.36 | -1.29 | -1.20 | -1.04 |
| Average Basic Shares Outstanding | 79.77M | 75.54M | 73.36M | 72.00M | 71.92M |
| Average Diluted Shares Outstanding | 79.77M | 75.54M | 73.36M | 72.00M | 71.92M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |